The story of multinational companies in Qingdao | AstraZeneca United Kingdom: favorable conditions, supportive policies, and an enabling environment are the confidence to increase investment in Qingdao
On June 18, the 6th Qingdao Multinationals Summit was held as scheduled.
In order to better tell the "Qingdao story" of the business environment
during the summit, Phoenix.com Qingdao specially planned the special topic "Qingdao@World
Qingdao Stories of Multinational Companies". Tell new stories about multinational
companies choosing and investing in Qingdao through dialogue, convey to the world
the good news that Qingdao is building a first-class business environment, open
up channels for foreign capital to understand and choose Qingdao, and build a bridge
to enhance mutual trust.
Hu Yiqing, Vice President of AstraZeneca China and Head of Rare Disease Business Unit
On the eve of the 6th Qingdao Multinationals
Summit, on May 16, the Information Office of the Shandong Provincial Government
held a press conference with the theme of "Shandong in Action to Serving Multinational
Corporations". Interestingly, the press conference was held directly at the
AstraZeneca Qingdao Inhalation Aerosol Production and Supply Base located in Qingdao
High-tech Zone.
"It’s honored to have participated in the Qingdao
Summit for many consecutive years and to exchange development experiences in China
with leaders of other multinational companies. I also look forward to using the
platform of the summit to further deepen cooperation with partners from all walks
of life and jointly promote the innovation and development of China's pharmaceutical
industry." said Hu Yiqing, Vice President of AstraZeneca China and Head of
Rare Disease Business Unit.
During the Qingdao Summit last year, AstraZeneca initiated
the "Shandong Rare Disease Industry Development Alliance" to promote exchanges
and integration among government, industry, academia, research, medicine and investment,
and support the creation of a regional industrial innovation highland.
When it comes to rare diseases, AstraZeneca is collaborating
with multiple partners in Shandong to promote early screening and diagnosis, while
supporting the establishment of Centers of Excellence (CoE) for rare diseases to
enhance standardized treatment. To date, AstraZeneca has supported the creation
of 133 rare disease CoE across China, including 10 in Shandong province, three of
which are located in Qingdao.
In Shandong,
AstraZeneca enjoys a bond as steadfast as that of "old friends" among
multinational corporations. The company has repeatedly increased its investments
in Qingdao and has participated in all five sessions of the Qingdao Multinationals
Summit. It can be said that AstraZeneca exemplifies the deep integration of multinational
corporations with Qingdao's economy.
"Shandong and Qingdao boast prime geographical positioning, robust industrial
foundations, and comprehensive manufacturing systems. In recent years, they have
vigorously developed the biopharmaceutical industry, introduced numerous policies
and measures, and continuously optimized the business environment. Moreover, the
government’s commitment to supporting foreign enterprises, along with its dedicated,
professional, and efficient services, reinforces our determination to grow in Shandong
and Qingdao," praised Hu Yiqing.
It is precisely
these "favorable conditions, supportive policies, and an enabling environment"
that have enabled AstraZeneca to expand its footprint and investments in recent
years.
In Qingdao, AstraZeneca
has established a regional headquarters (one of its five regional headquarters globally)
and invested $750 million to build an inhalation aerosol manufacturing and supply
base. Additionally, the Qingdao sub-fund under the AstraZeneca-CICC Medical Industry
Fund was launched late last year, raising RMB 1 billion in capital. The fund has
already completed its first investment, which was secured in Qingdao High-Tech Zone.
At this year's Qingdao Summit, AstraZeneca announced further plans to increase its
investments in Qingdao.
Comments
Post a Comment